Lifetime Cost-Effectiveness of Adjuvant External Beam Whole Breast Irradiation (EBWBI) in Estrogen Receptor Positive (ER+) Early-Stage Breast Cancer (ESBC) Women: Cardiotoxicity Consideration

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.04.209
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Treatment Constraints for Single Dose External Beam Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer

Clinical and Translational Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2017English

Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2015English

Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2013English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Intraoperative Radiation Therapy Versus Hypofractionated Whole Breast Irradiation in T1N0, ER Positive Patients

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Factors Determining Anthracycline Use in Hormone Receptor Positive, Early Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2019English

Medical Oncologists’ Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer

Annals of Oncology
MedicineOncologyHematology
2018English

Accelerated Whole Breast Irradiation in Early Breast Cancer Patients With Adverse Prognostic Features

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy